La vendita allo scoperto per Lunai Bioworks dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Lunai Bioworks. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Report sulle vendite allo scoperto

Lunai Bioworks Inc. - Common Stock

Lunai Bioworks

Panoramica

Notizie

Utili

Opzioni

Vendite allo scoperto

Rapporto azionario

Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

									Get Alert
LNAI	Lunai Bioworks Inc. Common Sto	10/31/2025	11/11/2025	0.84%	19,488,825	163,317	153,536	1.06	Get Alert
LNAI	Lunai Bioworks Inc. Common Sto	10/15/2025	10/24/2025	1.04%	19,488,825	202,666	270,775	1	Get Alert

Comments

Lunai Bioworks Rapporto sugli interessi allo scoperto

Vendite allo scoperto

Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO